Studies
Enrolling Studies
All Studies
Expand your treatment options and enhance your practice by integrating clinical trials. Gain access to a diverse portfolio of studies, sourced from over 20 industry sponsors, and broaden the care you can offer your community. Our tailored approach to trial matching ensures your patients are connected with studies that meet their specific needs, allowing them to explore the latest advancements in care and discover how clinical trials can directly benefit their health journey. Find available trials nearby and empower your patients with access to cutting-edge treatments.
CA239-0008
This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.
ASTRIDE (HLX10-005-SCLC301-E)
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
20210023
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
20190341 CODEBREAK202
The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.